Nabla Bio, Inc.
Nabla Bio is a company focused on advancing AI and experimental technologies for drug design, particularly in antibody development. They aim to expand the universe of druggable targets by integrating AI-guided design with wet-lab measurement, enabling the design of drugs with superior manufacturability, safety, and efficacy. Their mission is to generate new therapeutic opportunities through innovative protein and drug design technologies.
Industries
Nr. of Employees
small (1-50)
Nabla Bio, Inc.
Riverside Technology Center 840 Memorial Dr Cambridge, MA 02139
Patents
Systems and methods for rational protein engineering with deep representation learning
US-12040050-B1
View Details
Systems and methods for rational protein engineering with deep representation learning
US-12040050-B1
View DetailsProducts
AI-guided drug design and wet-lab measurement integration
Nabla Bio integrates AI for drug design with empirical wet-lab measurements to develop drugs with improved manufacturability, safety, and efficacy.
Generative modeling for drug candidates
The company uses generative models to create drug candidates targeting specific epitopes, conformations, and specificities, especially for challenging targets like multipass membrane proteins.
Partnering & licensing
Nabla Bio collaborates with pharmaceutical companies to develop and license biologics for difficult disease targets, leveraging their platform for drug design.
High-throughput and multiplex cell-based assays
Develops and performs assays for evaluating antibody function, including engineering cell lines and analyzing measurements using various techniques.
Antibody expression, purification, and developability measurement
Focuses on scaling antibody production and testing, including expression, purification, and assessing biophysical traits for development candidates.
Antibody engineering and developability measurement pipeline
Designs and executes DNA library cloning, yeast display selections, and optimizes therapeutic candidates for desired properties.
AI-guided drug design and wet-lab measurement integration
Nabla Bio integrates AI for drug design with empirical wet-lab measurements to develop drugs with improved manufacturability, safety, and efficacy.
Generative modeling for drug candidates
The company uses generative models to create drug candidates targeting specific epitopes, conformations, and specificities, especially for challenging targets like multipass membrane proteins.
Partnering & licensing
Nabla Bio collaborates with pharmaceutical companies to develop and license biologics for difficult disease targets, leveraging their platform for drug design.
High-throughput and multiplex cell-based assays
Develops and performs assays for evaluating antibody function, including engineering cell lines and analyzing measurements using various techniques.
Antibody expression, purification, and developability measurement
Focuses on scaling antibody production and testing, including expression, purification, and assessing biophysical traits for development candidates.
Antibody engineering and developability measurement pipeline
Designs and executes DNA library cloning, yeast display selections, and optimizes therapeutic candidates for desired properties.
Services
End-to-end platform combining generative protein design models with high-throughput experimental screening and characterization to discover and prioritize antibody leads, including against challenging membrane targets.
Collaborative partnerships and licensing arrangements to apply the platform to external targets or to license developed biologic molecules to drug development partners.
End-to-end platform combining generative protein design models with high-throughput experimental screening and characterization to discover and prioritize antibody leads, including against challenging membrane targets.
Collaborative partnerships and licensing arrangements to apply the platform to external targets or to license developed biologic molecules to drug development partners.
Expertise Areas
- De novo antibody design
- Generative protein design
- Machine learning for protein engineering
- High-throughput and multiplexed screening
Key Technologies
- Deep learning / protein language models
- Next-generation sequencing (NGS)
- Yeast display
- Flow cytometry (FACS) / MACS
News & Updates
A technical report on the advancements in de novo antibody design using test-time scaling.
An article discussing Nabla Bio's progress in AI-driven antibody development.
A blog post about the development of JAM, a new AI system for de novo antibody design.
A news article about Nabla Bio's funding and collaborations.
A press release about Nabla Bio's Series A funding and partnerships.
An article about Nabla Bio's seed funding.
A technical report on the advancements in de novo antibody design using test-time scaling.
An article discussing Nabla Bio's progress in AI-driven antibody development.
A blog post about the development of JAM, a new AI system for de novo antibody design.
A news article about Nabla Bio's funding and collaborations.
A press release about Nabla Bio's Series A funding and partnerships.
An article about Nabla Bio's seed funding.